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ABSTRACT Studies in yeast are providing
critical insights into the mechanisms of neurode-
generation in Parkinson’s disease (PD). A recent
study shows that disruption of vesicular traf-
ﬁcking between the endoplasmic reticulum (ER)
and the Golgi, caused by the overexpression
and/or aggregation of -synuclein, is linked to
degeneration of dopamine neurons. Overexpres-
sion of proteins that are known to enhance ER-to-
Golgi transport rescue defective trafﬁcking in
yeast, worm, ﬂy, and cellular models of PD.
T he failure of proteins to fold correctlyor to remain folded is the primarycause of several systemic and neuro-
degenerative diseases that affect a signiﬁ-
cant portion of theworld’s population (1). To
protect against aberrant folding, living
organisms have evolved efﬁcient protein
synthesis and quality-control machinery.
This system relies on close cooperation
between the chaperone and the protein-
degradation machinery to ensure control
over proper folding, targeting, and degrad-
ing of proteins.
Protein folding occurs in the cytosol or
within the lumen of the endoplasmic reticu-
lum (ER). Proteins that are destined to go
through the secretory pathway must pass
through a series of quality-control check-
points to ensure their correct processing
and targeting to the extracellular space, the
plasmamembrane, or their ﬁnal destination
within the cell (Figure 1). The ﬁrst check-
point along this pathway resides in the ER,
where soluble proteins are translated into
the ER lumen and transmembrane proteins
are translated and integrated into the ER
membrane. Concomitant to translation, a
specialized set of chaperones and the
quality-control machinery of the ER ensure
correct folding. In addition, post-transla-
tional modiﬁcations such as disulﬁde
bonds or N-linked glycosylations are intro-
duced.Once aprotein is properly folded and
modiﬁed andhas passed the quality-control
process, it is directed to a specialized ERexit
site, where it is integrated into transport
vesicles that bud from the ER membrane.
These vesicles are anterogradely trans-
ported to the Golgi, where they dock and
fuse with the membrane of the cis-Golgi
(see ref 2 for a detailed description of traf-
ﬁcking at the ER and Golgi apparatus). The
major function of theGolgi is to ﬁne-tune the
added sugar residues and to sort the differ-
ent cargo proteins into particular vesicles to
be transported along distinguished trafﬁck-
ing pathways. These include routes to the
plasma membrane for secretion and inser-
tion of surface proteins or to other intracellu-
lar compartments such as the endosomal/
lysosomal system. Each transport step also
engages in a retrograde transport activity.
This is particularly important for transport
between the ER and the Golgi in order to
recapture components of the vesicle-
trafﬁcking machinery and ER resident
proteins.
However, this process is not perfect, and
many newly synthesized proteins misfold
and rapidly degrade. Proteins that fail to fold
properly are retrotranslocated at the level of
the ER to the cytosol for degradation by the
ubiquitin proteasome system (UPS). If the
ER folding machinery and the UPS cannot
keep up with protein misfolding, the accu-
mulation and/or aggregation of misfolded
proteins induces cellular stress by multiple
mechanisms. The result is cellular dysfunc-
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tion, the initiation of ER-induced apoptosis,
and ultimately disease manifestation.
Several misfolding diseases are caused
by mutations that result in the loss of
protein function due to improper folding,
trafﬁcking, and/or enhanced intracellular
degradation by the UPS (e.g., cystic ﬁbrosis,
sickle-cell anemia, -1-antitrypsin deﬁ-
ciency, familial hypercholesterolemia, and
some forms of cancer) (1). If the rate of
protein misfolding is faster than that of deg-
radation because of mutations and/or
impaired quality-control machinery within
the cell, then the misfolded proteins accu-
mulate and self-associate to form highly
ordered -sheet-rich toxic aggregates. The
presence of aggregates of misfolded protein
in the form of intracellular inclusions or
extracellular deposits in the vicinity of dying
neurons is a deﬁning hallmark of several
neurodegenerative diseases (NDDs), includ-
ing Alzheimer’s disease (AD), Parkinson’s
disease (PD), amyotrophic lateral sclerosis,
and polyglutamine and prion diseases (3).
Increasing evidence from neuropatho-
logic, genetic, animal modeling, biochemi-
cal, and biophysical sources points toward
protein misfolding and aggregation as the
primary cause of several NDDs. However,
the exact mechanisms by which these pro-
cesses cause neurodegeneration and cell
death remain a subject of intense investiga-
tion and debate. Studies on cellular and
animal models of protein-aggregation dis-
eases suggest that thepathogenesis is com-
plicated, and it is likely that neurodegenera-
tion occurs by more than one mechanism.
Oxidative stress, membrane disruption, ER
stress, altered chaperone activity, impair-
ment of the UPS, mitochondrial deﬁcit, tran-
scriptional dysregulation, axonal transport
abnormalities, and Golgi fragmentation are
all possible consequences of protein aggre-
gation and are thought to play key roles in
the initiation and/or progression of neuro-
degeneration.
Yeast Sheds Light on Neurodegeneration
in PD. The discovery of disease-associated
mutations in the genes encoding the aggre-
gating proteins inspired the development of
genetic animal and cellular models as tools
for understanding the relationship between
protein aggregation and disease. The exist-
ing genetic models of protein aggregation
diseases are all based on the massive over-
expression of the gene coding for the wild-
type protein or disease-associated mutants
in mouse, rat, Drosophila, and Caenorhab-
ditis elegans. These models recapitulate
some features of the disease, but none has
been shown to reproduce the complete
disease phenotype observed in humans.
Baker’s yeast (Saccharomyces cerevi-
siae), a single-celled organism with6000
genes, was once thought to be too simple
for modeling complex pathologies of the
nervous system, but it is now emerging as a
powerful tool for modeling NDDs. Despite
signiﬁcant differences between yeast cells
and neurons, many of the basic cellular pro-
cesses, such as protein folding and the
quality-control machinery, are conserved in
both eukaryotic cells. In a recent study pub-
lished in Science Express, Antony Cooper
(University of Missouri, Kansas City), Susan
Lindquist’s team (Massachusetts Institute of
Technology), and colleagues from several
other research groups (4) took advantage of
these similarities by using a yeast model to
elucidate a new molecular mechanism
underlying the pathogenesis of PD. This
neurodegenerative movement disorder is
characterized by the loss of dopamine (DA)
neurons from the substantia nigra (SN) and
the formation of intraneuronal proteina-
ceous inclusions, referred to as Lewy
bodies (LBs).
-Synuclein Aggregation and Defective
Trafﬁcking. Lindquist and colleagues (4, 5)
created a yeast model of PD based on
Figure 1. Vesicular trafﬁcking in neurons. a) The extended morphology of neurons showing the cell body, dendrites, axons, and two synapses that
are the contact sites with upstream or downstream cells in the network. b) Like all eukaryotic cells, neurons possess a set of organelles that form
the secretory pathway. Protein synthesis takes place on ribosomes that associate with the ER membrane. Chaperones assist in proper folding of
these newly translated polypeptide chains. A complex quality-control machinery that recognizes misfolded proteins allows only correctly folded
proteins to reach ER exit sites, where transport vesicles containing the cargo proteins are formed. These vesicles are transported to the cis-side of
the Golgi, where they dock and fuse with its membrane. This process is dependent on the small GTPase Rab1. After further protein modiﬁcation,
cargo proteins are packaged into speciﬁc vesicles that take on diverse transport routes in the cell.
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increased expression of the presynaptic
protein -synuclein, the primary constituent
of LBs. Expression of mutant -synuclein or
the wild-type protein is sufﬁcient to cause
familial PD (6–9). -Synuclein aggregation
andﬁbrillogenesis are also implicated in the
pathogenesis of several NDDs, includingAD,
multiple-system atrophy, dementia with
LBs, Down syndrome, and neurodegenera-
tion with brain iron accumulation, collec-
tively referred to as synucleinopathies (10).
In the yeast system, the expression of
-synuclein (wild-type or disease-
associated mutant A53T) can be tightly
experimentally regulated and its effects
monitored in real time; thus, detection of
the early events involved in -synuclein tox-
icity is possible (4). Within the ﬁrst 4–8 h,
the presence of -synuclein aggregates and
increased ER stress were observed to coin-
cide with growth arrest and loss of cell
viability. ER and proteasome-speciﬁc sub-
strates were used to show that the expres-
sion of -synuclein does not affect the
general proteasome activity. However, it sig-
niﬁcantly impairs the turnover of substrates
for which degradation requires trafﬁcking
from the ER to the Golgi as well as the trans-
port of proteins that trafﬁc through this
pathway. Detailed dissection of the early
events occurring during the ﬁrst 4 h demon-
strated that the ﬁrst detectable defects in
cell growth coincide with the impairment of
vesicular transport from the ER to the Golgi
and occur before the induction of ER stress.
Rescuing Defective Vesicular Trafﬁcking.
Next, Lindquist and colleagues performed a
complementation screen for modiﬁers of
-synuclein toxicity, which identiﬁed 34
genes that suppressed -synuclein toxicity
and 20 genes that increased it. Many sup-
pressor genes that were speciﬁc for -syn-
uclein toxicity encode proteins that are also
involved in ER-to-Golgi transport. If toxicity
from increased -synuclein levels and/or
aggregationoccurs throughdisruptionof the
ER-to-Golgi transport machinery, then pro-
moting the forward transport from the ER to
the Golgi should reverse -synuclein toxic-
ity. Indeed, this was the case. This was par-
ticularly striking with Ypt1p and Rab1 (the
human homologue of Ypt1p). In yeast, Dro-
sophila, C. elegans, and rat DA neurons, the
overexpression of Ypt1p/Rab1 resulted in
signiﬁcant reduction of -synuclein-induced
neurodegeneration.
The small GTPases of the Rab family play
essential roles in vesicle docking and fusion
(Figure 2, panel c) (11). Rab1 has been
shown to be speciﬁcally involved in ER-to-
Golgi trafﬁcking and the docking of ER-
derived transport vesicles at the Golgi mem-
brane. This suggests that the transport step
affected by -synuclein toxicity is vesicle
docking/fusion at the Golgi membrane. The
colocalization of Ypt1p with -synuclein in
cytosolic inclusion suggests that -syn-
uclein toxicitymay involve the sequestration
of proteins that play a critical role in the
ER-to-Golgi transport and, eventually, the
Figure 2. Potential toxic mechanisms linking protein aggregation, defective trafﬁcking, and
selective degeneration of DA neurons in PD. a) Schematic depiction of the current understanding
of the aggregation pathway of -synuclein based on in vitro biophysical studies. b) DA oxidation
results in the production of reactive oxygen species and quinone and semiquinone intermedi-
ates, all of which are highly cytotoxic. To protect against the toxic properties of DA metabolites,
the majority of DA is stored in vesicles before its release. c) The study by Cooper et al. shows
that -synuclein aggregates interfere with a Rab1-dependent step of ER-to-Golgi transport. This
could lead to fragmentation of the Golgi due to an imbalance of incoming and outgoing vesicles,
reduced targeting of DA transporters to synaptic vesicles in the presynaptic terminal, and, as a
consequence, reduced uptake of DA into vesicles and an accumulation of DA in the cytosol.
Formation of toxic DAQ intermediates has been shown to covalently modify -synuclein and
enhance -synuclein toxicity through the kinetic stabilization of toxic preﬁbrillar aggregates.
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Colocalization of Ypt1p with -synuclein suggests that
-synuclein toxicity may involve the sequestration of
proteins that play a critical role in the ER-to-Golgi transport.
disruption of the secretory pathway. Further
biochemical and biophysical characteriza-
tion of the -synuclein aggregates could
provide important insights into the mecha-
nismof-synuclein toxicity in yeast.Whether
-synuclein has a physiological role in
ER-to-Golgi trafﬁcking or transport of syn-
aptic vesicles remains to be determined.
-Synuclein-Induced Disruption of ER-
to-Golgi Transport. Given the essential role
of the Golgi apparatus in the processing and
targeting of proteins through the secretory
pathway, any disruption at this level is likely
to have detrimental consequences for the
function of the cell. Furthermore, a delicate
balance between anterograde and retro-
grade membrane trafﬁc through the Golgi is
critical to avoid its fragmentation. A link
between -synuclein aggregation and Golgi
fragmentation is supportedbypreviousﬁnd-
ings demonstrating that formation of
-synuclein aggregates, particularly preﬁ-
brillar aggregates that precede LB formation
(Figure 2, panel a), causes fragmentation of
the Golgi in cellularmodels of synucleinopa-
thies (12) as well as in nigral neurons of PD
patients (13). Further studies are required to
elucidate the exact mechanisms by which
-synuclein aggregationdisrupts ER-to-Golgi
transport and cause Golgi fragmentation.
Defective Vesicular Trafﬁcking and DA
Neurons. Although -synuclein is an abun-
dant protein in different parts of the brain
(up to 1% of total proteins), -synuclein
aggregation in PD occurs primarily in DA
neurons of the SN. The wide distribution of
-synuclein in the brain suggests that
-synuclein on its own cannot explain the
selective degeneration of DA neurons in PD.
Overexpression of human -synuclein in
transgenic ﬂies (14) or speciﬁcally in the SN
of rats (15) and primates (16) results in
selective DA neuronal death and in the for-
mation of -synuclein-containing inclusions.
Overexpression of PD-linked -synuclein
mutations inhumanmesencephalic cell lines
leads to an impaired storage and secretion of
DA, causing an increase in cytosolic DA and
enhanced oxidative stress (17, 18). Xu et al.
(19) reported that blocking DA synthesis in
cultured DA neurons prevents -synuclein
toxicity, consistent with toxicity being medi-
ated by interactions between the two mol-
ecules. These observations are consistent
with the known hypersensitivity of DA
neurons that express high levels of cytoplas-
mic DA (e.g., the SN rather than the ventral
tegmental area) to cell death in PD.
The selective vulnerability of DA neurons
of the SN to -synuclein toxicity in PD may
be related to the toxicity and increased con-
centration of cytoplasmic DA in these cells;
this suggests that improper packaging,
secretion, and/or oxidation of DA might
explain the selective degeneration of DA
neurons (17, 18). DA oxidation and forma-
tion of DA orthoquinone (DAQ) in vitro
covalently modiﬁes -synuclein and results
in kinetic stabilization of toxic -synuclein
aggregates (20). Therefore, the simulta-
neous contributionof several factors, includ-
ing-synuclein oligomerization, DAmetabo-
lism, and oxidative stress, might be required
for selective degeneration of DA in the SN of
PD brains. Disruption of vesicular trafﬁcking
is likely to hasten cell death by simulta-
neously increasing the levels of cytosolic DA
and enhancing -synuclein aggregation.
The ﬁndings by Cooper and colleagues
offer new insight into the mechanisms by
which -synuclein overexpression and/or
aggregation interferes with normal function
and viability of neurons and reveal new
targets for therapeutic intervention in PD
and related synucleinopathies. In addition
to being a good model with which to study
genetic diseases, the yeast system is also
demonstrated by these researchers to offer
an excellent platform on which to screen for
druglike molecules as modiﬁers of -synu-
clein function(s), aggregation, and toxicity.
The identiﬁcation of speciﬁc pharmacologi-
calagents thatsuppress-synuclein-induced
ER-to-Golgi trafﬁcking defects and prevent or
reverse neurodegeneration in mousemodels
of PD as well as in clinical studies is the ulti-
mate proof of the therapeutic potential of
these ﬁndings.
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